These findings have been challenged by arguments pointing to the role of MMR mutations in tumor initiation, such as the discovery of a loss of expression of MMR proteins in apparently normal crypts in 25–35% of patients with LS-related CRC [162,163,164]. This evidence concerns the gene MRC1 and Leigh syndrome.